Johnson & Johnson Reports 2012 Fourth-Quarter and Full-Year Results:

2012 Fourth-Quarter Sales of $17.6 Billion increased 8.0%; EPS was $0.91
2012 Full-Year Sales of $67.2 Billion increased 3.4%; Full-Year EPS was $3.86
Excluding Special Items, 2012 Fourth-Quarter EPS was $1.19, an increase of 5.3%*
And 2012 Full-Year EPS was $5.10, an increase of 2.0%*

NEW BRUNSWICK, N.J., Jan. 22, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $17.6 billion for the fourth quarter of 2012, an increase of 8.0% as compared to the fourth quarter of 2011. Operational results increased 9.3% and the negative impact of currency was 1.3%. Domestic sales increased 6.8%, while international sales increased 8.9%, reflecting operational growth of 11.2% and a negative currency impact of 2.3%. Sales for the fourth quarter of 2012 included the impact of the recently completed acquisition of Synthes, Inc., which contributed 5.6% to worldwide operational sales growth, net of the divestiture of the DePuy trauma business. Worldwide sales for the full-year 2012 were $67.2 billion, an increase of 3.4% versus 2011. Operational sales increased 6.1% and the negative impact of currency was 2.7%.  Domestic sales increased 3.2%, while international sales increased 3.5%, reflecting operational growth of 8.4% and a negative currency impact of 4.9%. Sales for the full-year 2012 included the impact of the recently completed acquisition of Synthes, Inc., which contributed 3.1% to worldwide operational sales growth, net of the divestiture of the DePuy trauma business.

Net earnings and diluted earnings per share for the fourth quarter of 2012 were $2.6 billion and $0.91, respectively.** Fourth-quarter 2012 net earnings included after-tax special items of $0.8 billion, primarily related to an increase in the litigation accrual and program costs associated with the DePuy ASR Hip, in-process research and development, and integration and transaction costs related to the acquisition of Synthes, Inc. 

Fourth-quarter 2011 net earnings reflect after-tax special items of $2.9 billion as detailed in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items for both periods, net earnings for the current quarter were $3.4 billion and diluted earnings per share were $1.19, representing increases of 7.9% and 5.3%, respectively, as compared to the same period in 2011.*                                        

Net earnings and diluted earnings per share for the full-year 2012 were $10.9 billion and $3.86, respectively.** Full-year net earnings reflect after-tax special items of $3.5 billion in 2012 and $4.2 billion in 2011 as detailed in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items in both periods, net earnings for the full-year 2012 were $14.3 billion and diluted earnings per share were $5.10, representing increases of 3.4% and 2.0%, respectively, as compared with the full year of 2011.*                                                     

"Johnson & Johnson delivered solid results in 2012 reflecting continued sales momentum in many parts of our business driven by our focus on delivering meaningful innovation in health care to patients and customers. Our results included strong growth of key products, successful new product launches, and the addition of Synthes to our family of companies," said Alex Gorsky, Chairman and Chief Executive Officer. "In addition, we continued to make important investments building strategic partnerships and in advancing our pipeline, positioning us well for delivering sustainable growth as we enter 2013. I would also like to thank our talented colleagues at Johnson & Johnson for their extraordinary achievements in helping advance health and well-being for patients and customers around the world."

The Company announced earnings guidance for full-year 2013 of $5.35 to $5.45 per share, which excludes the impact of special items.

Worldwide Consumer sales of $14.4 billion for the full-year 2012 represented a decrease of 2.9% versus the prior year, consisting of an operational increase of 0.5% and a negative impact from currency of 3.4%. Domestic sales decreased 2.0%; international sales decreased 3.4%, which reflected an operational increase of 1.9% and a negative currency impact of 5.3%.

Positive contributors to operational results were sales of upper respiratory over-the-counter products; international sales of LISTERINE® oral care products; and U.S. sales of NEUTROGENA® skin care products.  

Worldwide Pharmaceutical sales of $25.4 billion for the full-year 2012 represented an increase of 4.0% versus the prior year with an operational increase of 6.8% and a negative impact from currency of 2.8%. Domestic sales increased 0.3%; international sales increased 7.9%, which reflected an operational increase of 13.6% and a negative currency impact of 5.7%.                                             

Primary contributors to operational sales growth were REMICADE® (infliximab), a biologic approved for the treatment of a number of immune-mediated, inflammatory diseases; VELCADE® (bortezomib), a treatment for multiple myeloma; PREZISTA® (darunavir), a treatment for HIV; and a number of recently launched products.

The strong sales results of recently launched products included ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the acute and maintenance treatment of schizophrenia in adults; international sales of  INCIVO® (telaprevir), a direct acting antiviral protease inhibitor, for the treatment of genotype-1 chronic hepatitis C virus, in combination with peginterferon alfa and ribavirin, in adults; STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; XARELTO® (rivaroxaban), an oral anticoagulant; and SIMPONI® (golimumab), a biologic approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Sales results were negatively impacted by generic competition for LEVAQUIN® (levofloxacin), a treatment for bacterial infections and the manufacturing suspension at a third party supplier for DOXIL® (doxorubicin HCl liposome injection)/CAELYX® (pegylated liposomal doxorubicin hydrochloride), a medication to treat ovarian and other cancers.

During the quarter, the U.S. Food and Drug Administration (FDA) granted accelerated approval for SIRTURO™ (bedaquiline) tablets for the treatment of pulmonary multi-drug resistant tuberculosis as part of combination therapy in adults. The FDA and the European Commission also approved an expanded indication for ZYTIGA® (abiraterone acetate), in combination with prednisone, allowing for the use before chemotherapy in the treatment of metastatic castration-resistant disease.

In November, the FDA approved XARELTO® (rivaroxaban), an oral anticoagulant, for the treatment of deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and to reduce the risk of recurrence of DVT and PE following initial treatment. In addition, the FDA approved a new 800mg tablet of PREZISTA® (darunavir) for once daily oral administration for the treatment of human immunodeficiency virus (HIV-1) in treatment-naive and treatment-experienced adult patients with no darunavir resistance-associated mutations.

Also during the quarter, a New Drug Application was submitted to the FDA seeking approval for a fixed-dose therapy combining canagliflozin and immediate release metformin to treat patients with type 2 diabetes. Additional submissions included a supplemental Biologics License Application to the FDA and a Type II Variation to the European Medicines Agency requesting approval of STELARA® (ustekinumab) for the treatment of adult patients with active psoriatic arthritis.

Worldwide Medical Devices and Diagnostics sales of $27.4 billion for the full-year 2012 represented an increase of 6.4% versus the prior year with an operational increase of 8.7% and a negative impact from currency of 2.3%. Domestic sales increased 8.7%; international sales increased 4.5%, which reflected an operational increase of 8.6% and a negative currency impact of 4.1%. Sales included the impact of the recently completed acquisition of Synthes, Inc., which contributed 7.9% to worldwide operational sales growth, net of the divestiture of the DePuy trauma business. 

Primary contributors to operational growth were sales from the recently completed acquisition of Synthes, Inc. in the Orthopaedics business; a number of products in the Specialty Surgery business; Biosense Webster's electrophysiology products in the Cardiovascular Care business; and Vistakon's disposable contact lenses.

During the quarter, the FDA approved EVARREST™ Fibrin Sealant Patch, a novel product that rapidly and reliably aids in stopping problematic bleeding during surgery. The FDA also approved the S.M.A.R.T.® CONTROL® Vascular Stent Systems for use in the superficial femoral artery and/or the proximal popliteal artery.                                              

About Johnson & Johnson
Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share attributable to Johnson & Johnson, excluding special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the financial schedules accompanying this press release and can be found in the Investor Relations section of the Company's website at www.investor.jnj.com.

 ** Net earnings and diluted earnings per share attributable to Johnson & Johnson.

NOTE TO INVESTORS

Johnson & Johnson will conduct a meeting with members of the investment community to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm.  These schedules include supplementary sales data, condensed consolidated statements of earnings, and sales of key products/franchises.  Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and medical devices and diagnostics pipeline of selected products, can be found on the Company's website at www.jnj.com

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation or government action; impact of business combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2012.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson.  Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)  

 

Johnson & Johnson and Subsidiaries















Supplementary Sales Data








































(Unaudited; Dollars in Millions)

FOURTH QUARTER


TWELVE MONTHS






Percent Change






Percent Change


2012


2011


Total


Operations


Currency


2012


2011


Total


Operations


Currency

Sales to customers by




















segment of business








































Consumer




















    U.S.

$     1,203


1,248


(3.6)

%

(3.6)


-


$    5,046


5,151


(2.0)

%

(2.0)


-

    International

2,449


2,420


1.2


3.2


(2.0)


9,401


9,732


(3.4)


1.9


(5.3)


3,652


3,668


(0.4)


0.9


(1.3)


14,447


14,883


(2.9)


0.5


(3.4)





















Pharmaceutical




















    U.S.

3,013


2,887


4.4


4.4


-


12,421


12,386


0.3


0.3


-

    International

3,512


3,207


9.5


12.1


(2.6)


12,930


11,982


7.9


13.6


(5.7)


6,525


6,094


7.1


8.5


(1.4)


25,351


24,368


4.0


6.8


(2.8)





















Med Devices & Diagnostics




















    U.S.

3,244


2,850


13.8


13.8


-


12,363


11,371


8.7


8.7


-

    International

4,137


3,643


13.6


15.8


(2.2)


15,063


14,408


4.5


8.6


(4.1)


7,381


6,493


13.7


14.9


(1.2)


27,426


25,779


6.4


8.7


(2.3)





















U.S.

7,460


6,985


6.8


6.8


-


29,830


28,908


3.2


3.2


-

International

10,098


9,270


8.9


11.2


(2.3)


37,394


36,122


3.5


8.4


(4.9)

Worldwide

$   17,558


16,255


8.0

%

9.3


(1.3)


$ 67,224


65,030


3.4

%

6.1


(2.7)

Johnson & Johnson and Subsidiaries
















Supplementary Sales Data








































(Unaudited; Dollars in Millions)

FOURTH QUARTER


TWELVE MONTHS






Percent Change






Percent Change


2012


2011


Total


Operations


Currency


2012


2011


Total


Operations


Currency

Sales to customers by




















geographic area








































U.S.

$ 7,460


6,985


6.8

%

6.8


-


$ 29,830


28,908


3.2

%

3.2


-





















Europe

4,603


4,279


7.6


10.4


(2.8)


16,945


17,129


(1.1)


5.8


(6.9)

Western Hemisphere excluding U.S.

1,941


1,688


15.0


18.7


(3.7)


7,207


6,418


12.3


19.0


(6.7)

Asia-Pacific, Africa

3,554


3,303


7.6


8.5


(0.9)


13,242


12,575


5.3


6.7


(1.4)

International

10,098


9,270


8.9


11.2


(2.3)


37,394


36,122


3.5


8.4


(4.9)





















Worldwide

$ 17,558


16,255


8.0

%

9.3


(1.3)


$ 67,224


65,030


3.4

%

6.1


(2.7)

 

Johnson & Johnson and Subsidiaries







Condensed Consolidated Statement of Earnings 
















(Unaudited; in Millions Except Per Share Figures)

FOURTH QUARTER












2012


2011


Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$   17,558


100.0


$    16,255


100.0


8.0

Cost of products sold

6,003


34.2


5,338


32.8


12.5

Selling, marketing and administrative expenses

5,661


32.2


5,458


33.6


3.7

Research and development expense

2,331


13.3


2,155


13.3


8.2

In-process research and development

55


0.3


-


-



Interest (income) expense, net

89


0.5


148


0.9



Other (income) expense, net

319


1.8


2,858


17.6



Restructuring (income) expense, net

-


-


(20)


(0.1)



Earnings before provision for taxes on income

3,100


17.7


318


1.9


874.8

Provision for taxes on income

533


3.1


100


0.6


433.0

Net earnings

2,567


14.6


218


1.3


1,077.5

Add: Net loss attributable to noncontrolling interest

-


-


-


-



Net earnings attributable to Johnson & Johnson

$     2,567


14.6


$         218


1.3


1,077.5











Net earnings per share attributable to Johnson & Johnson (Diluted)

$       0.91




$        0.08




1,037.5











Average shares outstanding (Diluted)

2,833.4




2,768.9















Effective tax rate

17.2

%



31.4

%














Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson (1)




   Earnings before provision for taxes on income

$     4,115


23.4


$      3,657


22.5


12.5

   Net earnings attributable to Johnson & Johnson

$     3,376


19.2


$      3,129


19.2


7.9

   Net earnings per share attributable to Johnson & Johnson (Diluted)

$       1.19




$        1.13




5.3

   Effective tax rate

18.0

%



14.4

%














(1) See Reconciliation of Non-GAAP Financial Measures.








 

Johnson & Johnson and Subsidiaries








Condensed Consolidated Statement of Earnings 

















(Unaudited; in Millions Except Per Share Figures)

TWELVE MONTHS












2012


2011


Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$    67,224


100.0


$    65,030


100.0


3.4

Cost of products sold

21,658


32.2


20,360


31.3


6.4

Selling, marketing and administrative expenses

20,869


31.0


20,969


32.3


(0.5)

Research and development expense

7,665


11.4


7,548


11.6


1.6

In-process research and development

1,163


1.7


-


-



Interest (income) expense, net

468


0.7


480


0.7



Other (income) expense, net

1,626


2.5


2,743


4.2



Restructuring (income) expense, net

-


-


569


0.9



Earnings before provision for taxes on income

13,775


20.5


12,361


19.0


11.4

Provision for taxes on income

3,261


4.9


2,689


4.1


21.3

Net earnings

10,514


15.6


9,672


14.9


8.7

Add: Net loss attributable to noncontrolling interest

339


0.5


-


-



Net earnings attributable to Johnson & Johnson

$    10,853


16.1


$      9,672


14.9


12.2











Net earnings per share attributable to Johnson & Johnson (Diluted)

$        3.86




$        3.49




10.6











Average shares outstanding (Diluted)

2,812.6




2,775.3















Effective tax rate

23.7

%



21.8

%














Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson (1)





   Earnings before provision for taxes on income

$    18,214


27.1


$    17,353


26.7


5.0

   Net earnings attributable to Johnson & Johnson

$    14,345


21.3


$    13,867


21.3


3.4

   Net earnings per share attributable to Johnson & Johnson (Diluted)

$        5.10




$        5.00




2.0

   Effective tax rate

21.2

%



20.1

%














(1) See Reconciliation of Non-GAAP Financial Measures.










 

Johnson & Johnson and Subsidiaries











Reconciliation of Non-GAAP Financial Measures



























Fourth Quarter


% Incr. /



Twelve Months 


% Incr. /


(Dollars in Millions Except Per Share Data)


2012


2011


(Decr.)



2012


2011


(Decr.)

















Earnings before provision for taxes on income - as reported


$  3,100


318


874.8

%


$   13,775


12,361


11.4

%
















Net litigation loss (gain)


471


2,656





1,229


3,310



















In-process research and development


55


14





1,163


14



















Synthes integration/transaction costs and currency related


406


277





1,028


491



















Intangible asset write-downs and other adjustments


-


-





909


-



















DePuy ASR™ Hip program


83


412





110


521



















Restructuring 


-


(20)





-


656



















Earnings before provision for taxes on income - as adjusted


$  4,115


3,657


12.5

%


$ 18,214


17,353


5.0

%
















Net Earnings attributable to Johnson & Johnson - as reported


$  2,567


218


1,077.5

%


$10,853


9,672


12.2

%
















Net litigation loss (gain)


371


2,239





1,052


2,745



















In-process research and development


59


11





743

(1)

11



















Synthes integration/transaction costs and currency related


306


338





899


477



















Intangible asset write-downs and other adjustments


-


-





701


-



















DePuy ASR™ Hip program


73


336





97


426



















Restructuring 


-


(13)





-


536



















Net Earnings attributable to Johnson & Johnson - as adjusted 


$  3,376


3,129


7.9

%


$ 14,345


13,867


3.4

%
















Diluted Net Earnings per share attributable to Johnson & Johnson - as reported


$    0.91


0.08


1,037.5

%


$      3.86


 

3.49


 

10.6

 

%


















Net litigation loss (gain)


0.13


0.81





0.37


0.99



















In-process research and development


0.02


-





0.27


-



















Synthes integration/transaction costs and currency related


0.11


0.12





0.32


0.17



















Intangible asset write-downs and other adjustments


-


-





0.25


-



















DePuy ASR™ Hip program


0.02


0.12





0.03


0.16



















Restructuring 


-


-





-


0.19



















Diluted Net Earnings per share attributable to Johnson & Johnson - as adjusted 


$   1.19


1.13


5.3

%


 

$    5.10


 

5.00


 

2.0

 

%

































(1) Amount includes third quarter in-process research and development charge of $679M related to bapineuzumab IV offset by $339M reported as net loss attributable to noncontrolling interest
















The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes 


on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.






 


REPORTED SALES vs. PRIOR PERIOD ($MM)








% Change




% Change


2012

2011

Reported

Operational (1)

Currency


2012

2011

Reported

Operational (1)

Currency

CONSUMER SEGMENT (2) 












BABY CARE












US

$     103

103

0.0%

0.0%

-


$       412

418

-1.4%

-1.4%

-

Intl

469

465

0.9%

3.5%

-2.6%


1,842

1,922

-4.2%

1.1%

-5.3%

WW

572

568

0.7%

2.8%

-2.1%


2,254

2,340

-3.7%

0.6%

-4.3%

ORAL CARE












US

165

173

-4.6%

-4.6%

-


641

656

-2.3%

-2.3%

-

Intl

251

239

5.0%

6.6%

-1.6%


983

968

1.5%

6.9%

-5.4%

WW

416

412

1.0%

2.0%

-1.0%


1,624

1,624

0.0%

3.2%

-3.2%

OTC/NUTRITIONALS












US

356

370

-3.8%

-3.8%

-


1,424

1,429

-0.3%

-0.3%

-

Intl

802

766

4.7%

5.7%

-1.0%


2,930

2,973

-1.4%

3.4%

-4.8%

WW

1,158

1,136

1.9%

2.6%

-0.7%


4,354

4,402

-1.1%

2.1%

-3.2%

SKIN CARE












US

385

403

-4.5%

-4.5%

-


1,699

1,654

2.7%

2.7%

-

Intl

509

541

-5.9%

-3.4%

-2.5%


1,919

2,061

-6.9%

-2.0%

-4.9%

WW

894

944

-5.3%

-3.9%

-1.4%


3,618

3,715

-2.6%

0.1%

-2.7%

WOMEN'S HEALTH












US

82

89

-7.9%

-7.9%

-


336

439

-23.5%

-23.5%

-

Intl

325

309

5.2%

9.4%

-4.2%


1,289

1,353

-4.7%

2.3%

-7.0%

WW

407

398

2.3%

5.5%

-3.2%


1,625

1,792

-9.3%

-4.0%

-5.3%

WOUND CARE/OTHER












US

112

110

1.8%

1.8%

-


534

555

-3.8%

-3.8%

-

Intl

93

100

-7.0%

-8.0%

1.0%


438

455

-3.7%

0.6%

-4.3%

WW

205

210

-2.4%

-2.9%

0.5%


972

1,010

-3.8%

-1.8%

-2.0%













TOTAL CONSUMER












US

1,203

1,248

-3.6%

-3.6%

-


5,046

5,151

-2.0%

-2.0%

-

Intl

2,449

2,420

1.2%

3.2%

-2.0%


9,401

9,732

-3.4%

1.9%

-5.3%

WW

$  3,652

3,668

-0.4%

0.9%

-1.3%


$ 14,447

14,883

-2.9%

0.5%

-3.4%

























See footnotes at end of schedule












 


REPORTED SALES vs. PRIOR PERIOD ($MM)








% Change




% Change


2012

2011

Reported

Operational (1)

Currency


2012

2011

Reported

Operational (1)

Currency

PHARMACEUTICAL SEGMENT  (2) (4)












IMMUNOLOGY












US

$  1,448

1,401

3.4%

3.4%

-


$   5,972

5,751

3.8%

3.8%

-

Intl

528

395

33.7%

35.7%

-2.0%


1,902

1,047

81.7%

86.3%

-4.6%

WW

1,976

1,796

10.0%

10.4%

-0.4%


7,874

6,798

15.8%

16.9%

-1.1%

     REMICADE












     US 

871

776

12.2%

12.2%

-


3,583

3,276

9.4%

9.4%

-

     US Exports (3)

347

437

-20.6%

-20.6%

-


1,470

1,797

-18.2%

-18.2%

-

     Intl

286

215

33.0%

34.4%

-1.4%


1,086

419

*

*

-4.5%

     WW

1,504

1,428

5.3%

5.5%

-0.2%


6,139

5,492

11.8%

12.6%

-0.8%

     SIMPONI












     US

72

62

16.1%

16.1%

-


292

235

24.3%

24.3%

-

     Intl

109

57

91.2%

96.8%

-5.6%


315

175

80.0%

87.5%

-7.5%

     WW

181

119

52.1%

54.8%

-2.7%


607

410

48.0%

51.2%

-3.2%

     STELARA












     US

158

126

25.4%

25.4%

-


627

443

41.5%

41.5%

-

     Intl

111

81

37.0%

40.1%

-3.1%


398

295

34.9%

42.4%

-7.5%

     WW

269

207

30.0%

31.2%

-1.2%


1,025

738

38.9%

41.9%

-3.0%

     OTHER IMMUNOLOGY












     US

-

-

-

-

-


-

-

-

-

-

     Intl

22

42

-47.6%

-49.4%

1.8%


103

158

-34.8%

-33.0%

-1.8%

     WW

22

42

-47.6%

-49.4%

1.8%


103

158

-34.8%

-33.0%

-1.8%

INFECTIOUS DISEASES












US

236

210

12.4%

12.4%

-


974

1,401

-30.5%

-30.5%

-

Intl

620

506

22.5%

26.7%

-4.2%


2,220

1,788

24.2%

32.1%

-7.9%

WW

856

716

19.6%

22.6%

-3.0%


3,194

3,189

0.2%

4.6%

-4.4%

     INTELENCE












     US

46

45

2.2%

2.2%

-


176

163

8.0%

8.0%

-

     Intl

38

38

0.0%

1.7%

-1.7%


173

151

14.6%

22.2%

-7.6%

     WW

84

83

1.2%

2.0%

-0.8%


349

314

11.1%

14.8%

-3.7%

     LEVAQUIN/FLOXIN












     US

-

(6)

*

*

-


35

579

-94.0%

-94.0%

-

     Intl

10

11

-9.1%

-10.5%

1.4%


40

44

-9.1%

-5.8%

-3.3%

     WW

10

5

100.0%

97.2%

2.8%


75

623

-88.0%

-87.8%

-0.2%

     PREZISTA












     US

165

143

15.4%

15.4%

-


672

529

27.0%

27.0%

-

     Intl

188

173

8.7%

12.2%

-3.5%


742

682

8.8%

16.3%

-7.5%

     WW

353

316

11.7%

13.6%

-1.9%


1,414

1,211

16.8%

21.0%

-4.2%

     OTHER INFECTIOUS DISEASES












     US

25

28

-10.7%

-10.7%

-


91

130

-30.0%

-30.0%

-

     Intl

384

284

35.2%

40.5%

-5.3%


1,265

911

38.9%

47.3%

-8.4%

     WW

409

312

31.1%

35.9%

-4.8%


1,356

1,041

30.3%

37.7%

-7.4%













 


REPORTED SALES vs. PRIOR PERIOD ($MM)








% Change




% Change


2012

2011

Reported

Operational (1)

Currency


2012

2011

Reported

Operational (1)

Currency













NEUROSCIENCE












US

601

611

-1.6%

-1.6%

-


2,611

2,617

-0.2%

-0.2%

-

Intl

1,088

1,128

-3.5%

-1.6%

-1.9%


4,107

4,331

-5.2%

-0.8%

-4.4%

WW

1,689

1,739

-2.9%

-1.6%

-1.3%


6,718

6,948

-3.3%

-0.5%

-2.8%

     CONCERTA/METHYLPHENIDATE












     US

116

155

-25.2%

-25.2%

-


609

822

-25.9%

-25.9%

-

     Intl

127

119

6.7%

8.1%

-1.4%


464

446

4.0%

8.8%

-4.8%

     WW

243

274

-11.3%

-10.7%

-0.6%


1,073

1,268

-15.4%

-13.7%

-1.7%

     INVEGA












     US

76

66

15.2%

15.2%

-


299

285

4.9%

4.9%

-

     Intl

71

59

20.3%

23.0%

-2.7%


251

214

17.3%

22.0%

-4.7%

     WW

147

125

17.6%

18.9%

-1.3%


550

499

10.2%

12.2%

-2.0%

     INVEGA SUSTENNA/ XEPLION












     US

132

99

33.3%

33.3%

-


482

319

51.1%

51.1%

-

     Intl

96

36

*

*

-2.4%


314

59

*

*

-5.7%

     WW

228

135

68.9%

69.9%

-1.0%


796

378

*

*

-2.2%

     RISPERDAL CONSTA












     US

103

108

-4.6%

-4.6%

-


439

443

-0.9%

-0.9%

-

     Intl

255

277

-7.9%

-5.8%

-2.1%


986

1,140

-13.5%

-8.6%

-4.9%

     WW

358

385

-7.0%

-5.5%

-1.5%


1,425

1,583

-10.0%

-6.4%

-3.6%

     OTHER NEUROSCIENCE












     US

174

183

-4.9%

-4.9%

-


782

748

4.5%

4.5%

-

     Intl

539

637

-15.4%

-13.7%

-1.7%


2,092

2,472

-15.4%

-11.9%

-3.5%

     WW

713

820

-13.0%

-11.7%

-1.3%


2,874

3,220

-10.7%

-8.0%

-2.7%

ONCOLOGY












US

135

95

42.1%

42.1%

-


506

331

52.9%

52.9%

-

Intl

684

468

46.2%

49.7%

-3.5%


2,123

1,717

23.6%

29.7%

-6.1%

WW

819

563

45.5%

48.5%

-3.0%


2,629

2,048

28.4%

33.3%

-4.9%

     DOXIL/CAELYX












     US

21

10

*

*

-


43

140

-69.3%

-69.3%

-

     Intl

9

29

-69.0%

-68.3%

-0.7%


40

262

-84.7%

-83.5%

-1.2%

     WW

30

39

-23.1%

-22.6%

-0.5%


83

402

-79.4%

-78.6%

-0.8%

     VELCADE












     US

-

-

-

-

-


-

-

-

-

-

     Intl

502

352

42.6%

47.6%

-5.0%


1,500

1,274

17.7%

24.5%

-6.8%

     WW

502

352

42.6%

47.6%

-5.0%


1,500

1,274

17.7%

24.5%

-6.8%

     ZYTIGA












     US

114

85

34.1%

34.1%

-


463

191

*

*

-

     Intl

150

67

*

*

-3.8%


498

110

*

*

-7.0%

     WW

264

152

73.7%

75.8%

-2.1%


961

301

*

*

-3.7%

     OTHER ONCOLOGY












     US

-

-

-

-

-


-

-

-

-

-

     Intl

23

20

15.0%

18.8%

-3.8%


85

71

19.7%

25.5%

-5.8%

     WW

23

20

15.0%

18.8%

-3.8%


85

71

19.7%

25.5%

-5.8%













 


REPORTED SALES vs. PRIOR PERIOD ($MM)








% Change




% Change


2012

2011

Reported

Operational (1)

Currency


2012

2011

Reported

Operational (1)

Currency

TOTAL OTHER












US

593

570

4.0%

4.0%

-


2,358

2,286

3.1%

3.1%

-

Intl

592

710

-16.6%

-15.5%

-1.1%


2,578

3,099

-16.8%

-12.4%

-4.4%

WW

1,185

1,280

-7.4%

-6.8%

-0.6%


4,936

5,385

-8.3%

-5.8%

-2.5%

     ACIPHEX/PARIET












     US

92

110

-16.4%

-16.4%

-


372

414

-10.1%

-10.1%

-

     Intl

94

144

-34.7%

-33.9%

-0.8%


463

561

-17.5%

-11.8%

-5.7%

     WW

186

254

-26.8%

-26.4%

-0.4%


835

975

-14.4%

-11.1%

-3.3%

     PROCRIT/EPREX












     US

171

191

-10.5%

-10.5%

-


805

814

-1.1%

-1.1%

-

     Intl

155

177

-12.4%

-11.0%

-1.4%


657

809

-18.8%

-13.7%

-5.1%

     WW

326

368

-11.4%

-10.7%

-0.7%


1,462

1,623

-9.9%

-7.4%

-2.5%

     OTHER












     US

330

269

22.7%

22.7%

-


1,181

1,058

11.6%

11.6%

-

     Intl

343

389

-11.8%

-10.8%

-1.0%


1,458

1,729

-15.7%

-12.1%

-3.6%

     WW

673

658

2.3%

2.9%

-0.6%


2,639

2,787

-5.3%

-3.1%

-2.2%













TOTAL PHARMACEUTICAL












US

3,013

2,887

4.4%

4.4%

-